Andreas Maetzel, Ph.D. - Publications

Affiliations: 
2001 University of Toronto, Toronto, ON, Canada 
Area:
Public Health, Health Care Management

58 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Larose J, King J, Brosseau L, Wells GA, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, Loew L, Kenny GP. The effect of walking on cardiorespiratory fitness in adults with knee osteoarthritis. Applied Physiology, Nutrition, and Metabolism = Physiologie AppliquéE, Nutrition Et MéTabolisme. 38: 886-91. PMID 23855277 DOI: 10.1139/apnm-2012-0487  0.92
2013 Benucci M, Stam WB, Gilloteau I, Sennfält K, Leclerc A, Maetzel A, Lucioni C. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis. Clinical and Experimental Rheumatology. 31: 575-83. PMID 23711100  0.92
2012 Brosseau L, Wells GA, Kenny GP, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, De Angelis G, Chen L. The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis: a knowledge translation randomized controlled trial: part II: clinical outcomes. Bmc Public Health. 12: 1073. PMID 23234575 DOI: 10.1186/1471-2458-12-1073  0.92
2012 Brosseau L, Wells GA, Kenny GP, Reid R, Maetzel A, Tugwell P, Huijbregts M, McCullough C, De Angelis G, Chen L. The implementation of a community-based aerobic walking program for mild to moderate knee osteoarthritis (OA): a knowledge translation (KT) randomized controlled trial (RCT): Part I: The Uptake of the Ottawa Panel clinical practice guidelines (CPGs). Bmc Public Health. 12: 871. PMID 23061875 DOI: 10.1186/1471-2458-12-871  0.92
2012 Loew L, Brosseau L, Wells GA, Tugwell P, Kenny GP, Reid R, Maetzel A, Huijbregts M, McCullough C, De Angelis G, Coyle D. Ottawa panel evidence-based clinical practice guidelines for aerobic walking programs in the management of osteoarthritis. Archives of Physical Medicine and Rehabilitation. 93: 1269-85. PMID 22421624 DOI: 10.1016/j.apmr.2012.01.024  0.92
2010 Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A, McGeer A, Raboud J, Scales DC, Gojovic MZ, Krahn M. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience Vaccine. 28: 6210-6220. PMID 20643091 DOI: 10.1016/j.vaccine.2010.07.010  0.92
2010 Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, Krahn M. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. Plos Medicine. 7: e1000256. PMID 20386727 DOI: 10.1371/journal.pmed.1000256  0.92
2009 Boonen A, Maetzel A, Drummond M, Suarez-Almazor M, Harrison M, Welch V, Tugwell PS. The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology. The Journal of Rheumatology. 36: 2045-9. PMID 19738211 DOI: 10.3899/jrheum.090355  0.92
2009 Maetzel A. Determining the value of innovative pharmaceuticals at the hospital level Ejhp Practice. 15: 56-58.  0.92
2008 Sander B, Elliot-Gibson V, Beaton DE, Bogoch ER, Maetzel A. A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs. The Journal of Bone and Joint Surgery. American Volume. 90: 1197-205. PMID 18519311 DOI: 10.2106/JBJS.G.00980  0.92
2008 Boonen A, Patel V, Traina S, Chiou CF, Maetzel A, Tsuji W. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. The Journal of Rheumatology. 35: 662-7. PMID 18278836  0.92
2008 Clark P, Carlos F, Barrera C, Guzman J, Maetzel A, Lavielle P, Ramirez E, Robinson V, Rodriguez-Cabrera R, Tamayo J, Tugwell P. Direct costs of osteoporosis and hip fracture: An analysis for the Mexican healthcare system Osteoporosis International. 19: 269-276. PMID 18060586 DOI: 10.1007/s00198-007-0496-8  0.92
2007 Bansback N, Maetzel A, Drummond M, Anis A, Marra C, Conway P, Boers M, Tugwell P, Boonen A. Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. The Journal of Rheumatology. 34: 1178-83. PMID 17477483  0.92
2007 Osiri M, Kamolratanakul P, Maetzel A, Tugwell P. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis. Rheumatology International. 27: 1063-9. PMID 17440729 DOI: 10.1007/s00296-007-0342-5  0.92
2007 Osiri M, Maetzel A, Tugwell P. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand. The Journal of Rheumatology. 34: 57-63. PMID 17183621  0.92
2006 Li LC, Maetzel A, Davis AM, Lineker SC, Bombardier C, Coyte PC. Primary therapist model for patients referred for rheumatoid arthritis rehabilitation: a cost-effectiveness analysis. Arthritis and Rheumatism. 55: 402-10. PMID 16739183 DOI: 10.1002/art.21989  0.92
2005 Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A. Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. International Journal of Obesity (2005). 29: 517-23. PMID 15738932 DOI: 10.1038/sj.ijo.0802925  0.92
2005 Maetzel A. Cost-effectiveness analysis: out of touch with clinical reality? Arthritis and Rheumatism. 53: 3-4. PMID 15696549 DOI: 10.1002/art.20906  0.92
2005 Maetzel A. Cost-effectiveness estimates reported for tumor necrosis factor blocking agents in rheumatoid arthritis refractory to methotrexate--a brief summary. The Journal of Rheumatology. Supplement. 72: 51-3. PMID 15660469  0.92
2004 Maetzel A. The role of utilities in economic evaluations of Healthcare interventions - An introduction Zeitschrift Fur Rheumatologie. 63: 380-384. PMID 15517298 DOI: 10.1007/s00393-004-0658-4  0.92
2004 Stone MA, Maetzel A, Inman RD, Wright JG. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics Arthritis Care and Research. 51: 316-320. PMID 15188313  0.92
2004 Li LC, Maetzel A, Pencharz JN, Maguire L, Bombardier C. Use of mainstream nonpharmacologic treatment by patients with arthritis. Arthritis and Rheumatism. 51: 203-9. PMID 15077260 DOI: 10.1002/art.20244  0.92
2004 Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Annals of the Rheumatic Diseases. 63: 395-401. PMID 15020333 DOI: 10.1136/ard.2003.006031  0.92
2004 Maetzel A. Defining therapeutic success in rheumatoid arthritis clinical trials: from statistical significance to clinical significance. The Journal of Rheumatology. 31: 411-2. PMID 14994379  0.92
2004 Rüttimann S, Keck B, Hartmeier C, Maetzel A, Bucher HC. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 38: 348-56. PMID 14727204 DOI: 10.1086/380964  0.92
2003 Drummond M, Maetzel A, Gabriel S, March L. Towards a reference case for use in future economic evaluations of interventions in osteoarthritis. The Journal of Rheumatology. Supplement. 68: 26-30. PMID 14712619  0.92
2003 Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and Rheumatism. 49: 283-92. PMID 12794781 DOI: 10.1002/art.11121  0.92
2003 Maetzel A. Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 17: 335-8. PMID 12772009  0.92
2003 Maetzel A, Ruof J, Covington M, Wolf A. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics. 21: 501-12. PMID 12696990 DOI: 10.2165/00019053-200321070-00005  0.92
2003 Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, Wong JB, Gabriel SE. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: Defining a consensus-based reference case Journal of Rheumatology. 30: 891-896. PMID 12672224  0.92
2003 Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V, Tugwell P. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. The Journal of Rheumatology. 30: 886-90. PMID 12672223  0.92
2002 Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis and Rheumatism. 47: 655-61. PMID 12522841 DOI: 10.1002/art.10793  0.92
2002 Maetzel A. The challenges of estimating the national costs of osteoarthritis: are we making progress? The Journal of Rheumatology. 29: 1811-3. PMID 12233870  0.92
2002 Maetzel A, Li L. The economic burden of low back pain: a review of studies published between 1996 and 2001. Best Practice & Research. Clinical Rheumatology. 16: 23-30. PMID 11987929 DOI: 10.1053/berh.2001.0204  0.92
2002 Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. Pharmacoeconomics. 20: 61-70. PMID 11817993 DOI: 10.2165/00019053-200220010-00006  0.92
2001 Gabriel S, Drummond M, Suarez-Almazor ME, Ruff B, Guillemin F, Bombardier C, Boers M, Maetzel A, Ruof J, Cranney A, Marentette M, Tugwell P. OMERACT 5 Economics Working Group: summary, recommendations, and research agenda. The Journal of Rheumatology. 28: 670-3. PMID 11296980  0.92
2001 Ruof J, Merkesdal S, Huelsemann JL, Schoeffski O, Maetzel A, Mau W, Zeidler H. Cost assessment instruments in rheumatology: Evaluation of applied instrument characteristics Journal of Rheumatology. 28: 662-665. PMID 11296978  0.92
2001 Merkesdal S, Ruof J, Huelsemann JL, Schoeffski O, Maetzel A, Mau W, Zeidler H. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis Journal of Rheumatology. 28: 657-661. PMID 11296977  0.92
2000 Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford, England). 39: 975-81. PMID 10986302  0.92
2000 Roger L, Maetzel A, Bombardier C. Better observational studies make better economic evaluations [5] (multiple letters) Journal of Rheumatology. 27: 2052-2053. PMID 10955358  0.92
2000 Maetzel A, Johnson SH, Woodbury M, Bombardier C. Use of grade membership analysis to profile the practice styles of individual physicians in the management of acute low back pain. Journal of Clinical Epidemiology. 53: 195-205. PMID 10729692 DOI: 10.1016/S0895-4356(99)00120-1  0.92
2000 Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A, Tindall E, Offenberg H, Poiley J, Rutstein J, Dietz F, Brodsky A, Harris R, et al. Clinical improvement as reflected in measures of function and health- related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial Arthritis and Rheumatism. 43: 506-514. PMID 10728742 DOI: 10.1002/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U  0.92
1999 Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Annals of the Rheumatic Diseases. 58: I82-5. PMID 10577979  0.92
1999 Maetzel A, Bombardier C. Give observational studies a chance: better observational studies make better economic evaluations. The Journal of Rheumatology. 26: 2298-9. PMID 10555880  0.92
1999 Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, Thompson A, Wells G. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis and Rheumatism. 42: 1870-8. PMID 10513801 DOI: 10.1002/1529-0131(199909)42:9<1870::AID-ANR11>3.0.CO;2-D  0.92
1998 Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. The Journal of Rheumatology. 25: 2331-8. PMID 9858426  0.92
1998 Maetzel A, Ferraz MB, Bombardier C. A review of cost-effectiveness analyses in rheumatology and related disciplines. Current Opinion in Rheumatology. 10: 136-40. PMID 9567209 DOI: 10.1097/00002281-199803000-00009  0.92
1998 Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis and Rheumatism. 41: 16-25. PMID 9433865 DOI: 10.1002/1529-0131(199801)41:1<16::AID-ART3>3.0.CO;2-4  0.92
1997 Ferraz MB, Maetzel A, Bombardier C. A summary of economic evaluations published in the field of rheumatology and related disciplines. Arthritis and Rheumatism. 40: 1587-93. PMID 9324012 DOI: 10.1002/1529-0131(199709)40:9<1587::AID-ART7>3.0.CO;2-C  0.92
1997 Maetzel A, Mäkelä M, Hawker G, Bombardier C. Osteoarthritis of the hip and knee and mechanical occupational exposure--a systematic overview of the evidence. The Journal of Rheumatology. 24: 1599-607. PMID 9263158  0.92
1997 Maetzel A. Costs of illness and the burden of disease The Journal of Rheumatology. 24: 3-5. PMID 9002002  0.92
1996 Frank JW, Brooker AS, DeMaio SE, Kerr MS, Maetzel A, Shannon HS, Sullivan TJ, Norman RW, Wells RP. Disability resulting from occupational low back pain. Part II: What do we know about secondary prevention? A review of the scientific evidence on prevention after disability begins. Spine. 21: 2918-29. PMID 9112717 DOI: 10.1097/00007632-199612150-00025  0.92
1996 Frank JW, Kerr MS, Brooker AS, DeMaio SE, Maetzel A, Shannon HS, Sullivan TJ, Norman RW, Wells RP. Disability resulting from occupational low back pain. Part I: What do we know about primary prevention? A review of the scientific evidence on prevention before disability begins. Spine. 21: 2908-17. PMID 9112716 DOI: 10.1097/00007632-199612150-00024  0.92
1993 Hajjaj-Hassouni N, Maetzel A, Dougados M, Amor B. Comparison of patients evaluated for spondylarthropathy in France and Morocco Revue Du Rhumatisme (Ed. Francaise : 1993). 60: 420-425. PMID 8124275  0.92
1993 Dougados M, Berenbaum F, Maetzel A, Amor B. Prevention of acute anterior uveitis associated with spondylarthropathy induced by salazosulfapyridine Revue Du Rhumatisme (Ed. Francaise : 1993). 60: 81-83. PMID 7902159  0.92
1993 Dougados M, Berenbaum F, Maetzel A, Amor B. The use of sulfasalazine for the prevention of attacks of acute anterior uveitis associated with spondylarthropathy [4] Revue Du Rhumatisme (English Edition). 60: 80-82.  0.92
1993 Hajjaj-Hassouni N, Maetzel A, Dougados M, Amor B. A comparative study of patients evaluated for spondylarthropathy in France and Morocco Revue Du Rhumatisme (English Edition). 60: 341-346.  0.92
1992 Dougados M, Maetzel A, Mijiyawa M, Amor B. Evaluation of sulphasalazine in the treatment of spondyloarthropathies Annals of the Rheumatic Diseases. 51: 955-958. PMID 1358038 DOI: 10.1136/ard.51.8.955  0.92
Show low-probability matches.